Carcinoid, a term first applied to hormonally active tumors by Oberndorfer in 1907, follows a more benign clinical course than most other malignancies. Carcinoid of the small intestine, a well-differentiated neuroendocrine tumor, is the most common distal small bowel malignancy, with an occurrence rate of 1 case per 300 autopsies. Carcinoid tumors of the appendix account for 0.2-0.7% of all appendicectomies, and they are the most common tumor of the appendix, accounting for 80% of appendiceal growths.2 Even though the frequency of the primary tumor is high, the incidence of metastasis is quite low (1 metastasis per 300, 000 incidences). Common sites of metastatic spread include the regional mesenteric and para-aortic lymph nodes and the liver. With distant spread, especially to the liver, carcinoid syndrome can develop. The association of flushing, diarrhea, bronchoconstriction, and cardiac disease with carcinoid tumors was first reported by Thorson and colleagues in 1954.The findings that 5-hydroxytryptamine (serotonin) was present in carcinoid tumors and that patients with carcinoid syndrome excrete increased quantities of the serotonin metabolite, 5-hydroxyindoleacetic acid (5-HIAA) led to the hypothesis that the humoral manifestations of carcinoid syndrome could be attributed to the overproduction of serotonin by these tumors. However, serotonin is not the only mediator of the clinical syndrome. Other substances, such as the tachykinins, play a significant role in the different clinical characteristics of affected patients.